Finance

Lists
BLTE:NASDAQ
Belite Bio Inc
USD 193,61
+13,16%
(+22,52) 1D
USD 193,61
0,00% (0,00)
After hours
Closed: 4 Sep., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BLTE...
Open
USD 172,77
High
USD 193,88
Low
USD 172,77
Mkt. cap
7,80 mjd
Avg. vol.
170,30 k
Volume
738,95 k
52-wk high
USD 200,00
52-wk low
USD 65,00
EPS
-USD 2,85
Beta
-1,23
Shares outstanding
40,27 m
No. of employees
41
Open
USD 172,77
High
USD 193,88
Low
USD 172,77
Mkt. cap
7,80 mjd
Avg. vol.
170,30 k
Volume
738,95 k
52-wk high
USD 200,00
52-wk low
USD 65,00
EPS
-USD 2,85
Beta
-1,23
Shares outstanding
40,27 m
No. of employees
41
News stories
From web sources and news partners
About Belite Bio Inc
CEO-
Employees41
Founded2016
Headquarters-
SectorPharmaceutical industry
Websitebelitebio.com
Analyst ratings
Based on 7 analysts giving stock ratings to BLTE in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for BLTE in the last 3 months.
Highest
Current USD 193,61
USD 303,00 (+56,50%)
Average
USD 230,43 (+19,02%)
Lowest
USD 200,00 (+3,30%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whitney Ijem
Canaccord Genuity
Buy
Initiated
USD 303,00
+56,5%
09/04/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
USD 220,00
+13,6%
09/04/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
USD 214,00
+10,5%
09/03/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
USD 200,00
+3,3%
09/02/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
USD 206,00
+6,4%
08/17/2026
Michael Okunewitch
Maxim Group
Buy
Maintained
USD 200,00
+3,3%
08/14/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
USD 270,00
+39,5%
08/14/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
USD 217,00
+12,1%
03/03/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10,31 m
14,62 m
15,66 m
18,21 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12,71 m
13,45 m
17,02 m
16,69 m
Operating expense
23,02 m
28,08 m
32,68 m
34,91 m
Total operating expenses
23,02 m
28,08 m
32,68 m
34,91 m
Operating income
-23,02 m
-28,08 m
-32,68 m
-34,91 m
Other non operating income
-2,14 m
-417,00 k
5,75 m
6,55 m
EBT including unusual items
-21,69 m
-25,32 m
-26,94 m
-28,36 m
EBT excluding unusual items
-21,69 m
-25,32 m
-26,94 m
-28,36 m
Income tax expense
-
-
-
55,00 k
Effective tax rate
-
-
-
-0,19%
Other operating expenses
-
-
-
-
Net income
-21,69 m
-25,32 m
-26,94 m
-28,41 m
Net profit margin
-
-
-
-
Earnings per share
-0,65
-0,70
-0,68
-0,70
Interest and investment income
3,47 m
3,17 m
-
-
Interest expense
-
-2,00 k
-
-
Net interest expenses
3,47 m
3,17 m
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-22,97 m
-28,03 m
-32,64 m
-34,86 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme